Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA

July 8th 2024

A panel of experts discuss the potential of individual tumor sequencing with bespoke testing methodologies.

The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

July 5th 2024

S. Lindsey Davis, MD, highlights data with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib in patients with solid tumors.

Murthy Highlights Second-Line Treatment Considerations in ER+/HER2– Metastatic Breast Cancer

July 4th 2024

Pooja Murthy, MD, discusses second-line treatments in ER+/HER2– metastatic breast cancer for patients following progression on endocrine therapy plus a CDK4/6 inhibitor.

OncLive’s June Roundup of Key FDA Approvals in Oncology

July 3rd 2024

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

Clinical Decision Making to Overcome Treatment Resistance in 2L HR+/HER2- Locally Advanced or Metastatic Breast Cancer

July 3rd 2024

The panel examines how resistance mutations influence the efficacy of subsequent treatment lines and delves into the process of selecting later-line therapies based on next-generation sequencing results.

Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway

July 2nd 2024

Key opinion leaders explore the mechanisms of resistance that can develop after endocrine therapy and CDK4/6 inhibitor treatment in HR+/HER2- locally advanced or metastatic breast cancer, emphasizing the uncertain etiology of resistance and current hypotheses, while also examining biomarkers that may predict resistance to CDK4/6 inhibitors and endocrine therapy.

Dr Tarantino on the Safety of T-DXd and T-DM1 in HER2+ Breast Cancer

July 2nd 2024

Paolo Tarantino, MD, discusses updated safety data from the phase 3 DESTINY-Breast03 trial of T-DXd in HER2+ breast cancer.

Dr Davis on the Potential For ADCs to Continue to Reshape Breast Cancer Treatment

July 2nd 2024

Andrew Davis, MD, discusses how antibody-drug conjugates could continue to reshape the breast cancer treatment paradigm.

Dual mTORC1/mTORC2 Inhibitor Sapanisertib Shows Promise in Combination Regimens for Solid Tumors

July 2nd 2024

Vivek Subbiah, MD, details the rationale for combining sapanisertib with ziv-aflibercept or metformin and next steps for mTOR inhibitors in solid tumors.

Case Presentation 1: PIK3CA Mutation With ESR1 Mutations

July 1st 2024

Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, present a patient case involving a 54-year-old postmenopausal woman diagnosed with a 2.1cm estrogen receptor positive (ER+), HER2 negative breast cancer, and discuss the clinical implications and management strategies for this specific patient scenario.

Dynamics of ESR1 Alterations and Serial Liquid Biopsies

July 1st 2024

In their discussion, medical experts in the field of breast cancer explore the role of liquid biopsies and compare the significance of ESR1 mutations to other biomarkers, such as PIK3CA, in terms of their driver versus passenger status in the context of HR+/HER2- breast cancer.

Clinical Impact of Subcutaneous Fixed-Dose Pertuzumab – trastuzumab-hyaluronidase in HER2+ Breast Cancer

July 1st 2024

Breast cancer specialists outline their institution’s practices regarding the choice between subcutaneous fixed-dose pertuzumab – trastuzumab-hyaluronidase and intravenous pertuzumab and trastuzumab.

Preoperative Monitoring and Surgical Options for HER2+ Patients

July 1st 2024

Kandace P. McGuire, MD, provides clinical insights on how patient monitoring practices inform discussions around surgical options, providing the potential for deescalating surgical management.

Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

July 1st 2024

A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.

Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer

July 1st 2024

A panel of experts discuss advancements in adjuvant therapy for early-stage breast cancer.

postMONARCH Meets Primary End Point of Improvement of PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression

June 29th 2024

Kevin Kalinsky, MD, MS, discusses the outcomes of the postMONARCH study in patients with HR+/HER2– breast cancer following disease progression.

Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2– Breast Cancer

June 28th 2024

Jason Abdou Mouabbi, MD, discusses considerations for the use of ribociclib vs abemaciclib in patients with HR-positive, HER2-negative breast cancer.

Dr Llombart-Cussac on Preventing Neutropenia and Diarrhea in HR+/HER2– Advanced Breast Cancer

June 28th 2024

Antonio Llombart-Cussac, MD, PhD, discusses preventing neutropenia and diarrhea with sacituzumab govitecan in HR+/HER2– advanced breast cancer.

FDA Approves Tepylute for Breast and Ovarian Cancer Treatment

June 28th 2024

The FDA has approved a new drug application for Tepylute, a ready-to-dilute formulation to treat breast and ovarian cancers.

Dr O'Shaughnessy on MammaPrint H1 vs H2 Status on 3-year RFS in HR+, HER2– Breast Cancer

June 27th 2024

Joyce O'Shaughnessy, MD, on the impact of MammaPrint H1 and H2 status on 3-year relapse-free survival in HR-positive, HER2-negative early breast cancer.